3 Stocks Pushing The Drugs Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 96 points (-0.6%) at 16,467 as of Friday, Aug. 1, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 828 issues advancing vs. 2,201 declining with 119 unchanged.

The Drugs industry currently sits down 1.7% versus the S&P 500, which is down 0.6%. On the negative front, top decliners within the industry include Novo Nordisk A/S ( NVO), down 2.6%, Biogen Idec ( BIIB), down 2.2%, Amgen ( AMGN), down 1.8%, Alexion Pharmaceuticals ( ALXN), down 1.6% and GlaxoSmithKline ( GSK), down 1.4%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Sanofi ( SNY) is one of the companies pushing the Drugs industry higher today. As of noon trading, Sanofi is up $0.60 (1.1%) to $52.87 on heavy volume. Thus far, 3.0 million shares of Sanofi exchanged hands as compared to its average daily volume of 924,400 shares. The stock has ranged in price between $52.76-$53.30 after having opened the day at $53.18 as compared to the previous trading day's close of $52.27.

Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Sanofi has a market cap of $138.2 billion and is part of the health care sector. Shares are down 2.5% year-to-date as of the close of trading on Thursday. Currently there are 2 analysts who rate Sanofi a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Sanofi Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Teva Pharmaceutical Industries ( TEVA) is up $0.30 (0.6%) to $53.80 on average volume. Thus far, 3.0 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 4.0 million shares. The stock has ranged in price between $53.44-$54.75 after having opened the day at $53.51 as compared to the previous trading day's close of $53.50.

Teva Pharmaceutical Industries Limited, together with its subsidiaries, develops, manufactures, sells, and distributes pharmaceutical products worldwide. The company offers generic pharmaceutical products; and basic chemicals, as well as specialized product families. Teva Pharmaceutical Industries has a market cap of $46.7 billion and is part of the health care sector. Shares are up 33.5% year-to-date as of the close of trading on Thursday. Currently there are 8 analysts who rate Teva Pharmaceutical Industries a buy, 1 analyst rates it a sell, and 9 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Teva Pharmaceutical Industries Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Regeneron Pharmaceuticals ( REGN) is up $9.43 (3.0%) to $325.65 on heavy volume. Thus far, 938,156 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 841,200 shares. The stock has ranged in price between $320.43-$328.73 after having opened the day at $323.74 as compared to the previous trading day's close of $316.22.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $31.9 billion and is part of the health care sector. Shares are up 14.9% year-to-date as of the close of trading on Thursday. Currently there are 7 analysts who rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Regeneron Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Global Stocks Slide as Trump's New Trade War Salvo Ignites Fresh Concern

Global Stocks Slide as Trump's New Trade War Salvo Ignites Fresh Concern

Ackman Investment Buoys Lowe's; DraftKings Responds to FanDuel Merger -- ICYMI

Ackman Investment Buoys Lowe's; DraftKings Responds to FanDuel Merger -- ICYMI

Replay: Jim Cramer on the Markets, Tiffany, Micron Technology and Union Pacific

Replay: Jim Cramer on the Markets, Tiffany, Micron Technology and Union Pacific

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market

Red Robin Slumps After Earnings Miss

Red Robin Slumps After Earnings Miss